首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1671846

肺動脈高血壓藥物市場按藥物類別、給藥途徑、類型、性別、通路和地區分類

Pulmonary Arterial Hypertension Drug Market, By Drug Class, By Route of Administration, By Type, By Gender, By Distribution Channel, By Geography

出版日期: 2025年02月26日 | 出版商:

Coherent Market Insights | 英文 163 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球肺動脈高血壓藥物市場規模估計為 85.8 億美元，預計到 2032 年將達到 128.1 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 5.9%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	85.8億美元
效能資料	從 2020 年到 2024 年	預測期	2025 至 2032 年
預測期：2025-2032年複合年成長率：	5.90％	2032 年價值預測	128.1億美元

數字。 2025 年肺動脈高血壓治療市場佔有率（按地區分類）

過去幾年，全球肺動脈高血壓藥物市場一直穩定成長。肺動脈高血壓是一種以連接心臟和肺部的動脈血壓異常高的疾病。過大的壓力會使心臟更難將血液泵入肺部以獲取氧氣。如果延遲治療，病情可能會惡化並導致心臟衰竭。由於風險因素的增加、新的有效治療藥物的核准以及診斷技術的改進，肺動脈高血壓盛行率不斷上升，推動了全球對特定藥物的需求。然而，治療費用高昂以及長期用藥的副作用仍然是主要挑戰。

市場動態：

全球肺動脈高血壓藥物市場受到多種因素的推動，例如由於人口老化、遺傳易感性和其他醫療狀況等風險因素的增加而導致肺動脈高血壓盛行率不斷上升。美國國家醫學圖書館估計，到2024年11月，北美和歐洲將有超過10萬人患有肺動脈高血壓。此外，前列腺環素類似物、內皮素受體拮抗劑和磷酸二酯酶 5 抑制劑等療效和便利性更高的新藥的核准也推動了市場的成長。然而，品牌藥物的高價格仍然是一個主要阻礙因素。治療肺動脈高血壓需要終生服藥，每年花費數千美元。這限制了人們獲得藥物的機會。不過，低成本學名藥的出現有望為市場參與者創造新的機會。

本研究的主要特點

本報告對全球肺動脈高血壓治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。

它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球肺動脈高血壓治療市場的主要企業是根據公司亮點、產品系列、關鍵亮點、業績和策略等參數進行介紹的。

這項研究涉及的主要企業包括 United Therapeutics Corporation、Actelion Pharmaceuticals（楊森製藥公司旗下一家）、拜耳公司、吉利德科學公司、默克公司、葛蘭素史克公司、輝瑞公司、諾華國際公司、Teva Pharmaceutical Industries Ltd.、安進公司、百時山公司、Arena Pharmaceticals、Arena Pharmaceticals.

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。

全球肺動脈高血壓治療藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過用於分析全球肺動脈高血壓藥物市場的各種策略矩陣來促進決策。

United Therapeutics Corporation
Actelion Pharmaceuticals
Bayer AG
Gilead Sciences, Inc.
Merck & Co., Inc.
GlaxoSmithKline plc
Pfizer Inc.
Novartis International AG
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
Bristol-Myers Squibb Company
Arena Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Sandoz Inc.
Lupin Pharmaceuticals, Inc.

第 11 章分析師建議

命運之輪
分析師觀點
一致的機會圖

第 12 章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI203

Global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at US$ 8.58 Bn in 2025 and is expected to reach US$ 12.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	US$ 8.58 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.90%	2032 Value Projection:	US$ 12.81 Bn

Figure. Pulmonary Arterial Hypertension Drug Market Share (%), By Region 2025

Pulmonary Arterial Hypertension Drug Market - IMG1

The global pulmonary arterial hypertension drug market has been witnessing steady growth over the past few years. Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure in the arteries connecting the heart and lungs. The excessive pressure makes the heart work harder to pump blood through the lungs to obtain oxygen. If not treated on time, the condition can lead to worsening symptoms and even heart failure. Factors such as the growing prevalence of pulmonary arterial hypertension due to increasing risk factors, approval of new and effective treatment drugs, and improved diagnosis are driving the demand for specific drugs globally. However, high treatment costs and side effects associated with long term use of drugs continue to remain major challenges.

Market Dynamics:

The global pulmonary arterial hypertension drug market is driven by factors such as the increasing prevalence of pulmonary arterial hypertension due to growing risk factors like older age, genetic predisposition, and other medical conditions. In November 2024, according to National Library of Medicine estimates, more than 100,000 people in North America and Europe suffer from pulmonary arterial hypertension. Furthermore, approval of new drugs such as prostacyclin analogs, Endothelin receptor antagonists, Phosphodiesterase-5 inhibitors, and others which offer improved efficacy and convenience is also fueling market growth. However, the high cost of branded drugs remains a key restraint. Treatment of pulmonary arterial hypertension requires life-long medication which costs thousands of dollars every year. This limits accessibility to medication. Nevertheless, emergence of low-cost generic drugs is expected to create new opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include United Therapeutics Corporation, Actelion Pharmaceuticals (a Janssen Pharmaceutical Company), Bayer AG, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Arena Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Sandoz Inc., and Lupin Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
- Soluble Guanylate Cyclase (sGC) Stimulators
- Other Drug Classes
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravenous
- Subcutaneous
- Inhalation
Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded Drugs
- Generic Drugs
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- United Therapeutics Corporation
- Actelion Pharmaceuticals
- Bayer AG
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Arena Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Sandoz Inc.
- Lupin Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Pulmonary Arterial Hypertension Drug Market, By Drug Class
- Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration
- Global Pulmonary Arterial Hypertension Drug Market, By Type
- Global Pulmonary Arterial Hypertension Drug Market, By Gender
- Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel
- Global Pulmonary Arterial Hypertension Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Pulmonary Arterial Hypertension Drug Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Prostacyclin and Prostacyclin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Endothelin Receptor Antagonists (ERAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Soluble Guanylate Cyclase (sGC) Stimulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Drug Classes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pulmonary Arterial Hypertension Drug Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pulmonary Arterial Hypertension Drug Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Pulmonary Arterial Hypertension Drug Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

United Therapeutics Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Actelion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
Bristol-Myers Squibb Company
Arena Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Sandoz Inc.
Lupin Pharmaceuticals, Inc.